AxoGen Inc. (AXGN) shares plummeted over 25% in pre-market trading on Wednesday following the company's fourth quarter results that missed expectations and a muted outlook for 2025.
The medical technology company focused on peripheral nerve repair reported revenue of $49.4 million for the fourth quarter of 2024, representing a 15.1% increase over the prior year. While this showed continued growth, it fell short of analysts' estimates.
Looking ahead, AxoGen provided full-year 2025 revenue guidance of 15-17% growth, which disappointed investors hoping for a more robust outlook after the company outlined an ambitious strategic plan targeting a 15-20% revenue CAGR over the next four years. Key growth initiatives included expanding in breast reconstruction, accelerating adoption in extremities and oral/maxillofacial markets, and developing new markets like nerve repair for prostatectomy procedures.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。